血清及胎盘中脂蛋白相关磷脂酶A2水平与妊娠期高血压疾病的关系

 目的 探讨血清及胎盘中脂蛋白相关磷脂酶A₂(Lp-PLA₂)与妊娠期高血压疾病的关系。方法 采用酶联免疫吸附法及免疫组织化学方法检测60例妊娠期高血压疾病患者(妊娠高血压19例、轻度子痫前期25例、重度子痫前期16例) 及20例正常妊娠妇女(对照组)血清及胎盘中Lp-PLA₂水平,并分析其与妊娠期高血压疾病的关系。结果 妊娠期高血压疾病组胎盘中Lp-PLA₂表达水平明显高于对照组(P<0.05)。轻度子痫前期组Lp-PLA₂表达水平显著高于对照组(P<0.05),重度子痫前期Lp-PLA₂表达水平显著高于轻度子痫前期组(P<0.05)。妊娠期高血压疾病组血清中Lp-PLA₂水平显著高于对照组(P<0.05)。随着病情的加重,Lp-PLA₂水平呈逐渐上升趋势,对照组、妊娠高血压、轻度子痫前期、重度子痫前期每两组之间比较,差异均有统计学意义(P均＜0.05)。妊娠期高血压疾病组血清与胎盘中Lp-PLA₂水平呈正相关(r=0.435,P<0.05)。结论 Lp-PLA₂水平的升高可能与妊娠期高血压疾病的发生有关,母血中Lp-PLA₂水平的变化有可能作为疾病的监测指标。

Relationship of Lp-PLA2 levels in maternal serum and placenta with hypertensive disorders of pregnancy

Objective To investigate the relationship between Lp-PLA2 levels in maternal serum and placenta and hypertensive disorders of pregnancy. Methods The levels of Lp-PLA2 in serum and placenta of 60 patients with hypertensive disorders of pregnancy (19 cases of gestational hypertension, 25 cases of mild preeclampsia, and 16 cases of severe preeclampsia) and 20 normal pregnant women (control group) were measured by enzyme-linked immunosorbent assay and immunohistochemistry. The relationship between levels of Lp-PLA2 and hypertensive disorders of pregnancy was analyzed. Results 1) The expression level of Lp-PLA2 in placenta of patients with hypertensive disorders of pregnancy was significantly higher than that of the control group (P<0.05), so was the expression level of Lp-PLA2 in the mild preeclampsia group (P<0.05). The level in the severe preeclampsia group was significantly higher than that of the mild preeclampsia group (P<0.05). 2) The level of maternal serum Lp-PLA2 was significantly higher than that of the control group(P<0.05). With the aggravation of the disease, the level of Lp-PLA2 increased gradually. There was significant difference between the two groups (all P<0.05). 3) There was a positive correlation between the levels of Lp-PLA2 in serum and in placenta of patients with hypertensive disorders of pregnancy (r=0.435, P< 0.05). Conclusions The increase of Lp-PLA2 levels may be related to the occurrence of hypertensive disorders of pregnancy. The change of Lp-PLA2 levels in maternal serum may be used as a monitoring indicator of the disease.